Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00766636 · ClinicalTrials.gov registry record · Phase 2
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00766636: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00766636 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00766636, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Primary Objective: To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of surgical margin on final pathology report") in patients treated with preoperative chemotherapy (gemcitabine and erlotinib) with or without external-beam radiation therapy followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Secondary Objectives: * To assess disease free survival * To assess overall survival * To assess patterns of local and distant failure
Interventions
- RADIATION Radiation Therapy
- DRUG Gemcitabine
- PROCEDURE Surgery
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00766636
The ClinicalTrials.gov registry entry for NCT00766636 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT00766636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00766636 about?
NCT00766636 is a clinical study titled "Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy". Primary Objective: To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of surgical margin on final pathology report") in patients treated with preoperative chemotherapy (gemcitabine and erlotinib) with or without external-beam radiation therapy followed by pan...
What is the current status of trial NCT00766636?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-09.
What interventions are being tested in trial NCT00766636?
The interventions under investigation include: Radiation Therapy (RADIATION), Gemcitabine (DRUG), Surgery (PROCEDURE), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00766636?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.